Abstract:Clusterin (CLU) or APOJ is a multifunctional glycoprotein that has been implicated in several physiological and pathological states, including Alzheimer's disease (AD). With a prominent extracellular chaperone function, additional roles have been discussed for clusterin, including lipid transport and immune modulation, and it is involved in pathways common to several diseases such as cell death and survival, oxidative stress, and proteotoxic stress. Although clusterin is normally a secreted protein, it has also been found intracellularly under certain stress conditions. Multiple hypotheses have been proposed regarding the origin of intracellular clusterin, including specific biogenic processes leading to alternative transcripts and protein isoforms, but these lines of research are incomplete and contradictory. Current consensus is that intracellular clusterin is most likely to have exited the secretory pathway at some point or to have re-entered the cell after secretion. Clusterin's relationship with amyloid beta (Aβ) has been of great interest to the AD field, including clusterin's apparent role in altering Aβ aggregation and/or clearance. Additionally, clusterin has been more recently identified as a mediator of Aβ toxicity, as evidenced by the neuroprotective effect of CLU knockdown and knockout in rodent and human iPSC-derived neurons. CLU is also the third most significant genetic risk factor for late onset AD and several variants have been identified in CLU. Although the exact contribution of these variants to altered AD risk is unclear, some have been linked to altered CLU expression at both mRNA and protein levels, altered cognitive and memory function, and altered brain structure. The apparent complexity of clusterin's biogenesis, the lack of clarity over the origin of the intracellular clusterin species, and the number of pathophysiological functions attributed to clusterin have all contributed to the challenge of understanding the role of clusterin in AD pathophysiology. Here, we highlight clusterin's relevance to AD by discussing the evidence linking clusterin to AD, as well as drawing parallels on how the role of clusterin in other diseases and pathways may help us understand its biological function(s) in association with AD.

Clusterin Inhibits Aβ42 Aggregation Through a “strawberry Model” As Detected by FRET‐FCS

Clusterin in Alzheimer’s disease: a player in the biological behavior of amyloid-beta

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Dissecting the Inhibitory Mechanism of the Αb-Crystallin Domain Against Aβ42 Aggregation and Its Effect on Aβ42 Protofibrils: A Molecular Dynamics Simulation Study

An Enzyme-Linked Immunosorbent Assay To Compare The Affinity Of Chemical Compounds For Beta-Amyloid Peptide As A Monomer

Oligomeric amyloid beta prevents myelination in a clusterin-dependent manner

Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Clusterin Is Required for β-Amyloid Toxicity in Human iPSC-Derived Neurons

An enzyme-linked immunosorbent assay to compare the affinity of chemical compounds for β-amyloid peptide as a monomer

Β-Amyloid Upregulates Intracellular Clusterin but Not Secretory Clusterin in Primary Cultured Neurons and APP Mice

Clusterin in Alzheimer's Disease

Differential Modulation of the Aggregation of N-terminal truncated Aβ via Cucurbiturils.

Alzheimer's disease protective allele of Clusterin modulates neuronal excitability through lipid-droplet-mediated neuron-glia communication

Characterization of Copper Interactions with Alzheimer Amyloid β Peptides: Identification of an Attomolar-Affinity Copper Binding Site on Amyloid β1-42

Molecular mechanisms of resveratrol and EGCG in the inhibition of A<sub>42</sub> aggregation and disruption of A<sub>42</sub> protofibril: similarities and differences

Identification of potential aggregation hotspots on Aβ42 fibrils blocked by the anti-amyloid chaperone-like BRICHOS domain

Rescue of Cognitive Deficits in APP/PS1 Mice by Accelerating the Aggregation of Β-Amyloid Peptide

Fibrillar Seeds Alleviate Amyloid-Β Cytotoxicity by Omitting Formation of Higher-Molecular-weight Oligomers

Structural, morphological, and kinetic studies of β-amyloid peptide aggregation on self-assembled monolayers.